6,264 Shares in Pfizer Inc. (PFE) Acquired by Nottingham Advisors Inc.

Nottingham Advisors Inc. acquired a new position in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 6,264 shares of the biopharmaceutical company’s stock, valued at approximately $224,000.

Several other institutional investors have also added to or reduced their stakes in PFE. Nwam LLC lifted its holdings in Pfizer by 5.3% in the 1st quarter. Nwam LLC now owns 53,786 shares of the biopharmaceutical company’s stock valued at $1,840,000 after purchasing an additional 2,699 shares in the last quarter. Searle & CO. lifted its holdings in Pfizer by 92.7% in the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after purchasing an additional 38,500 shares in the last quarter. HPM Partners LLC lifted its holdings in Pfizer by 1,561.3% in the 1st quarter. HPM Partners LLC now owns 106,341 shares of the biopharmaceutical company’s stock valued at $3,638,000 after purchasing an additional 99,940 shares in the last quarter. Insight 2811 Inc. lifted its holdings in Pfizer by 3.7% in the 1st quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock valued at $319,000 after purchasing an additional 329 shares in the last quarter. Finally, Loudon Investment Management LLC lifted its holdings in Pfizer by 406.8% in the 1st quarter. Loudon Investment Management LLC now owns 47,616 shares of the biopharmaceutical company’s stock valued at $1,629,000 after purchasing an additional 38,221 shares in the last quarter. Institutional investors and hedge funds own 69.75% of the company’s stock.

Pfizer Inc. (NYSE:PFE) opened at $36.21 on Wednesday. The firm has a market cap of $215,419.95, a PE ratio of 22.35, a PEG ratio of 2.55 and a beta of 1.01. Pfizer Inc. has a 1-year low of $30.90 and a 1-year high of $37.35. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.61 EPS. research analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current year.

Pfizer announced that its Board of Directors has initiated a stock buyback plan on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.76%. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is 79.01%.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,800 shares of company stock valued at $1,327,248. Corporate insiders own 0.06% of the company’s stock.

A number of research analysts have issued reports on PFE shares. UBS Group set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. BMO Capital Markets restated a “buy” rating and issued a $39.00 target price on shares of Pfizer in a report on Friday, November 10th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price on the stock in a report on Thursday, November 23rd. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a report on Tuesday, October 3rd. Finally, Jefferies Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $38.77.

WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2017/12/27/6264-shares-in-pfizer-inc-pfe-acquired-by-nottingham-advisors-inc.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit